Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun 5;18(1):252.
doi: 10.1186/s13063-017-1990-8.

Steroids in chronic subdural hematomas (SUCRE trial): study protocol for a randomized controlled trial

Pierre-Louis Henaux  1   2 , Pierre-Jean Le Reste  3   4 , Bruno Laviolle  5   6   4 , Xavier Morandi  3   4
Affiliations
Clinical Trial

Steroids in chronic subdural hematomas (SUCRE trial): study protocol for a randomized controlled trial

Pierre-Louis Henaux et al. Trials. .

Abstract

Background: Chronic subdural hematoma (CSDH) is a common neurological pathology, especially in older patients. The actual "gold standard" of treatment is surgical evacuation, with various techniques used across neurosurgical teams. Over the years, there has been growing evidence that inflammatory processes play a major role in the pathogenesis of CSDH. In that context, the use of corticosteroids has been proposed alone or as an adjuvant treatment to surgery. However, this practice remains very empirical and there is a need for high-quality-of-evidence studies to clarify the role of corticosteroids in the management of CSDH.

Methods/design: We propose a double-blind, randomized controlled trial comparing methylprednisolone versus placebo in the treatment of CSDH without clinical and/or radiological signs of severity. The treatment will be administered daily for a duration of 3 weeks, at a dose of 1 mg/kg. The primary endpoint will be the delay of occurrence of surgical treatment at 1 month following the introduction of the treatment. Secondary endpoints will include the rate of recourse to surgery, survival rate, quality of life and functional assessments, occurrence of systemic secondary effects and radiological assessment of the response to treatment. This multimodal assessment will be done at 1, 3 and 6 months. Two hundred and two patients (101 per arm) are expected to be included considering our primary hypotheses.

Discussion: This trial started in June 2016; its results may open interesting alternatives to surgery in the management of patients harboring a CSDH, and may provide insights into the natural history of this common pathology.

Trial registration: ClinicalTrials.gov, ID: NCT02650609 . Registered on 4 January 2016. Graphical output of the OBF boundaries.

Keywords: Chronic subdural hematoma; Conservative treatment; Corticosteroids; Elderly patients; Methylprednisolone.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study flow chart. *Plasma sodium, potassium, and fasting glycemia/**fasting plasma cortisol
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Santarius T, Kirkpatrick PJ, Kolias AG, Hutchinson PJ. Working toward rational and evidence-based treatment of chronic subdural hematoma. Clin Neurosurg. 2010;57:112–22. - PubMed
    1. Markwalder TM. Chronic subdural hematomas: a review. J Neurosurg. 1981;54:637–45. doi: 10.3171/jns.1981.54.5.0637. - DOI - PubMed
    1. Bourgeois P, Sleiman M, Louis E, Haddad E, Touzet G, Fichten A, Lejeune JP. Chronic subdural hematoma in patients over 80 years of age. Neurochirurgie. 1999;45:124–8. - PubMed
    1. Cousseau DH, Echevarría Martín G, Gaspari M, Gonorazky SE. Chronic and subacute subdural haematoma. An epidemiological study in a captive population. Rev Neurol. 2001;32:821–4. - PubMed
    1. Kinsella K, Velkoff V. An aging world: 2001. Washington DC: US Government Printing Office; 2001.

Publication types

MeSH terms

Associated data